Fennec Pharmaceuticals (FENC)

• Market cap: $182M
• 1 day: 0.76%
• 5 days: -2.49%
• 1 month: 15.85%
• 3 months: 40.89%
• 6 months: 18.12%
• Year to date: 5.72%
• 1 year: -25.11%
• 5 years: -12.96%
• 10 years: -44.58%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Employees: 29

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 14

36% more capital invested

Capital invested by funds: $74.7M [Q3] → $101M (+$26.7M) [Q4]

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

3.9% more ownership

Funds ownership: 54.61% [Q3] → 58.51% (+3.9%) [Q4]

2% more funds holding

Funds holding: 63 [Q3] → 64 (+1) [Q4]

8% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 12

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 95% upside
• Avg. target: $13 95% upside
• High target: $13 95% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 126 / 333 met price target

95% upside $13

Buy Reiterated

17 Dec 2024